ATE439359T1 - Inhibitoren der cdc25 phosphatase - Google Patents

Inhibitoren der cdc25 phosphatase

Info

Publication number
ATE439359T1
ATE439359T1 AT05826562T AT05826562T ATE439359T1 AT E439359 T1 ATE439359 T1 AT E439359T1 AT 05826562 T AT05826562 T AT 05826562T AT 05826562 T AT05826562 T AT 05826562T AT E439359 T1 ATE439359 T1 AT E439359T1
Authority
AT
Austria
Prior art keywords
inhibitors
cdc25 phosphatase
cdc25
phosphatase
dione
Prior art date
Application number
AT05826562T
Other languages
English (en)
Inventor
Alban Sidhu
Gregoire Prevost
Dennis Bigg
Contour Marie-Odile Galcera
Original Assignee
Ipsen Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma filed Critical Ipsen Pharma
Application granted granted Critical
Publication of ATE439359T1 publication Critical patent/ATE439359T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT05826562T 2004-12-17 2005-12-16 Inhibitoren der cdc25 phosphatase ATE439359T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0413456A FR2879598B1 (fr) 2004-12-17 2004-12-17 Inhibiteurs de phosphatases cdc25
PCT/FR2005/003161 WO2006067311A2 (fr) 2004-12-17 2005-12-16 Inhibiteurs de phosphatases cdc25

Publications (1)

Publication Number Publication Date
ATE439359T1 true ATE439359T1 (de) 2009-08-15

Family

ID=34954106

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05826562T ATE439359T1 (de) 2004-12-17 2005-12-16 Inhibitoren der cdc25 phosphatase

Country Status (15)

Country Link
US (1) US8017637B2 (de)
EP (1) EP1831209B1 (de)
JP (1) JP2008524175A (de)
AT (1) ATE439359T1 (de)
CA (1) CA2591215A1 (de)
CY (1) CY1109596T1 (de)
DE (1) DE602005016014D1 (de)
DK (1) DK1831209T3 (de)
ES (1) ES2331199T3 (de)
FR (1) FR2879598B1 (de)
PL (1) PL1831209T3 (de)
PT (1) PT1831209E (de)
RU (1) RU2395510C2 (de)
SI (1) SI1831209T1 (de)
WO (1) WO2006067311A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2834289B1 (fr) 2001-12-27 2004-03-19 Sod Conseils Rech Applic Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques
FR2877667B1 (fr) 2004-11-05 2007-03-23 Sod Conseils Rech Applic Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques
FR2879598B1 (fr) 2004-12-17 2007-03-30 Sod Conseils Rech Applic Inhibiteurs de phosphatases cdc25
FR2915747B1 (fr) * 2007-05-04 2011-02-25 Scras Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatase cdc25
FR2930552B1 (fr) * 2008-04-24 2012-10-12 Centre Nat Rech Scient N-acylthiourees et n-acylurees inhibiteurs de la voie de signalisation des proteines hedgehog
FR2945532A1 (fr) * 2009-05-15 2010-11-19 Ipsen Pharma Sas Derives de tri-amino-pyrimidine comme inhibiteurs de phosphatases cdc25
RU2441068C2 (ru) * 2010-03-11 2012-01-27 Галина Ивановна Эль-Регистан Способ направленного изменения активности ферментных белков
RU2441069C2 (ru) * 2010-03-11 2012-01-27 Галина Ивановна Эль-Регистан Стабилизатор ферментных белков
HRP20191860T1 (hr) 2013-03-13 2019-12-27 Forma Therapeutics, Inc. Derivati 2-hidroksi-1-{4-[(4-fenilfenil)karbonil]piperazin-1-il}etan-1-ona i srodni spojevi kao inhibitori sintaze masnih kiselina (fasn) za liječenje raka
WO2016046414A2 (en) 2014-09-26 2016-03-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Cdc25a inhibitor for the treatment of drug resistant cancer or for the prevention of tumor relapse
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
WO2020092395A1 (en) 2018-10-29 2020-05-07 Forma Therapeutics, Inc. SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE
WO2022018667A1 (en) 2020-07-24 2022-01-27 Pfizer Inc. Combination therapies using cdk2 and cdc25a inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1534275A (en) 1976-01-30 1978-11-29 Shell Int Research Herbicidal compositions containing 1,4-quinones or derivatives thereof
US5508289A (en) * 1994-03-14 1996-04-16 The United States America As Represented By The Department Of Health And Human Services Bis-acridone chemotherapeutic derivatives
US5523430A (en) 1994-04-14 1996-06-04 Bristol-Myers Squibb Company Protein farnesyl transferase inhibitors
US6673927B2 (en) 1996-02-16 2004-01-06 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Farnesyl transferase inhibitors
IT1293525B1 (it) * 1997-08-01 1999-03-01 Uni Degli Studi Camerino Bis-acridincarbossiammidi aventi attivita' antitumorale
AU1400401A (en) 1999-11-09 2001-06-06 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Product inhibiting transduction of G heterotrimeric protein signals combined with another anti-cancer agent for therapeutic use in cancer treatment
US20030130298A1 (en) 1999-12-21 2003-07-10 Chapdelaine Marc Jerome Cd45 inhibitors
FR2812198B1 (fr) * 2000-07-28 2008-07-18 Sod Conseils Rech Applic DERIVES D'AMIDINES INHIBITEURS DE PHOSPHATASES cdc25
AR037714A1 (es) 2001-12-06 2004-12-01 Maxia Pharmaceuticals Inc Derivados de tiazolidinona y oxazolidinona 2-sustituidos para la inhibicion de fosfatasas y el tratamiento de cancer
ES2290359T3 (es) * 2001-12-27 2008-02-16 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivados de benzotiazol- y benzoxazol-4,7-diona y su utilizacion como inhibidores de fosfatasas cdc25.
FR2834289B1 (fr) 2001-12-27 2004-03-19 Sod Conseils Rech Applic Derives de benzothiazole-4,7-diones et benzooxazole-4,7- diones, leur preparation et leurs applications therapeutiques
FR2856688B1 (fr) 2003-06-25 2008-05-30 Sod Conseils Rech Applic PRODUIT COMPRENANT AU MOINS UN INHIBITEUR DE PHOSPHATASE CDc25 EN ASSOCIATION AVEC AU MOINS UN AUTRE AGENT ANTI-CANCEREUX
FR2856686A1 (fr) 2003-06-25 2004-12-31 Sod Conseils Rech Applic Benzothiazole-4,7-diones et benzooxazole-4,7-diones substituees en position 5 ou 6 et leurs procedes de preparation
FR2877667B1 (fr) 2004-11-05 2007-03-23 Sod Conseils Rech Applic Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques
FR2879598B1 (fr) 2004-12-17 2007-03-30 Sod Conseils Rech Applic Inhibiteurs de phosphatases cdc25

Also Published As

Publication number Publication date
JP2008524175A (ja) 2008-07-10
DE602005016014D1 (de) 2009-09-24
PT1831209E (pt) 2009-11-04
DK1831209T3 (da) 2009-11-30
FR2879598B1 (fr) 2007-03-30
WO2006067311A3 (fr) 2006-08-17
FR2879598A1 (fr) 2006-06-23
US20090275624A1 (en) 2009-11-05
RU2007127250A (ru) 2009-01-27
SI1831209T1 (sl) 2010-01-29
CA2591215A1 (fr) 2006-06-29
RU2395510C2 (ru) 2010-07-27
PL1831209T3 (pl) 2010-01-29
WO2006067311A2 (fr) 2006-06-29
EP1831209B1 (de) 2009-08-12
ES2331199T3 (es) 2009-12-23
EP1831209A2 (de) 2007-09-12
CY1109596T1 (el) 2014-08-13
US8017637B2 (en) 2011-09-13

Similar Documents

Publication Publication Date Title
CY1109596T1 (el) Αναστολεις φωσφατασων cdc25
EA200701467A1 (ru) Пирролидиновые ингибиторы иап (ингибиторов апоптоза)
NO20081636L (no) FAP - inhibitorer
MX2021003843A (es) Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer.
NO20071127L (no) Triazoloftalaziner
PL1660507T5 (pl) Inhibitory proteazomu oraz sposoby ich stosowania
CY1108275T1 (el) Χημικες ενωσεις
TW200640924A (en) VEGF-R2 inhibitors and methods
ATE486870T1 (de) Jnk inhibitoren
IS7721A (is) Píperidín-pýrídasón og þalasón sem PDE4 hemlar
ATE400567T1 (de) Kinaseinhibitoren
MY146037A (en) Isoquinoline derivatives as inhibitors of rho-kinase
BRPI0606379A2 (pt) triazolftalazinas
ATE456571T1 (de) Proteasom-hemmer und verwendungsverfahren dafür
EA201170344A1 (ru) Азаиндольные ингибиторы iap
EA201000494A1 (ru) Новые гидрокси-8-гетероарилфенантридины и их применение в качестве ингибиторов pde4
MX2022000811A (es) Inhibidores de enzimas.
MX2010007543A (es) Inhibidores de iap.
UA85505C2 (en) Kinase inhibitors
EA200801145A1 (ru) Спироциклические производные хиназолина в качестве ингибиторов pde7
BRPI0615141A2 (pt) inibidores pentacìclicos de quinase
DK1814879T3 (da) Derivater af 4,7-dioxobenzothiazol-2-caboxamider, fremgangsmåde til fremstilling deraf og terapeutiske anvendelser af samme
UA94049C2 (ru) Применение ингибиторов glepp-1 для лечения аутоиммунных и/или воспалительных расстройств
EA200702584A1 (ru) Спиробензимидазолы как ингибиторы секреции соляной кислоты
ATE461189T1 (de) Neue 6-pyridylphenanthridine

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1831209

Country of ref document: EP